{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T01:41:59Z","timestamp":1648777319651},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychosomatics"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.psym.2011.06.001","type":"journal-article","created":{"date-parts":[[2013,9,9]],"date-time":"2013-09-09T18:52:48Z","timestamp":1378752768000},"page":"583-585","source":"Crossref","is-referenced-by-count":1,"title":["Severe INR Elevation Related to Duloxetine Use: A Case Report"],"prefix":"10.1016","volume":"52","author":[{"given":"Clifford","family":"Gimenez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garry","family":"Guce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandra","family":"Lingisetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leon","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.psym.2011.06.001_bib1","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions","volume":"165","author":"Holbrook","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.psym.2011.06.001_bib2","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2165\/00003088-200544120-00003","article-title":"Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon, and acenocoumarol","volume":"44","author":"Ufer","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.psym.2011.06.001_bib3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3346\/jkms.2010.25.3.337","article-title":"Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting","volume":"25","author":"Choi","year":"2010","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.psym.2011.06.001_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.clinthera.2011.01.021","article-title":"Evaluation of warfarin drug interaction listings in US product information for warfarin and interacting drugs","volume":"33","author":"Hines","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.psym.2011.06.001_bib5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/nedt.2007.3.2.193","article-title":"Duloxetine in the treatment of major depressive disorder","volume":"3","author":"Goldstein","year":"2007","journal-title":"Neuropsychiatry Dis Treat"},{"key":"10.1016\/j.psym.2011.06.001_bib6","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1001\/jama.295.13.1517","article-title":"Interaction of duloxetine and warfarin causing severe elevation of international normalized ratio","volume":"295","author":"Glueck","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.psym.2011.06.001_bib7","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.clinthera.2007.12.026","article-title":"Potential drug\u2013drug interaction between duloxetine and acenocoumarol in a patient with Alzheimer's disease","volume":"29","author":"Monastero","year":"2007","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.psym.2011.06.001_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.psym.2011.06.001_bib9","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1345\/aph.1H423","article-title":"Proposal for a new tool to evaluate drug interaction cases","volume":"41","author":"Horn","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.psym.2011.06.001_bib10","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1161\/01.CIR.0000063575.17904.4E","article-title":"AHA\/ACC Foundation Guide to warfarin Therapy","volume":"107","author":"Hirsch","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.psym.2011.06.001_bib11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00003088-200847030-00005","article-title":"In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine","volume":"47","author":"Lobo","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.psym.2011.06.001_bib12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1592\/phco.24.2.285.33137","article-title":"Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature","volume":"24","author":"Andrus","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.psym.2011.06.001_bib13","first-page":"1191","article-title":"In vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s","volume":"25","author":"Prueksaritanont","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.psym.2011.06.001_bib14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1592\/phco.27.5.675","article-title":"The effect of acetaminophen on the international normalized ratio in patients stabilized on warfarin therapy","volume":"27","author":"Parra","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.psym.2011.06.001_bib15","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1160\/TH04-02-0109","article-title":"Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle","volume":"92","author":"Thijssen","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.psym.2011.06.001_bib16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2125.2004.02199.x","article-title":"Paracetamol: a haemorrhagic risk factor in patients on warfarin","volume":"59","author":"Mah\u00e9","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.psym.2011.06.001_bib17","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.cgh.2006.04.018","article-title":"Case Report: fulminant hepatic failure involving duloxetine hydrochloride","volume":"4","author":"Hanje","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.psym.2011.06.001_bib18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2174\/157488608784529198","article-title":"Hepatic Effects of Duloxetine-II: Spontaneous Reports and Epidemiology of Hepatic Events","volume":"3","author":"Wernicke","year":"2008","journal-title":"Curr Drug Saf"},{"issue":"Suppl 6","key":"10.1016\/j.psym.2011.06.001_bib19","doi-asserted-by":"crossref","first-page":"257S","DOI":"10.1378\/chest.08-0674","article-title":"Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines 8th ed","volume":"133","author":"Schulman","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.psym.2011.06.001_bib20","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1111\/j.1476-5381.2009.00420.x","article-title":"Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs","volume":"158","author":"Choppin","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.psym.2011.06.001_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/13814780701815116","article-title":"Risk factors for potential drug interactions in general practice","volume":"14","author":"Bjerrum","year":"2008","journal-title":"Eur J Gen Pract"},{"key":"10.1016\/j.psym.2011.06.001_bib22","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00228-007-0326-0","article-title":"Potential drug interactions during a three-decade study period: a cross-sectional study of a prescription register","volume":"63","author":"Astrand","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.psym.2011.06.001_bib23","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1001\/archinte.167.16.1752","article-title":"Serious adverse drug events reported to the Food and Drug Administration, 1998\u20132005","volume":"167","author":"Moore","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.psym.2011.06.001_bib24","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/archinternmed.2008.3","article-title":"Frequency of and risk factors for preventable medication-related hospital admissions in The Netherlands","volume":"168","author":"Leendertse","year":"2008","journal-title":"Arch Intern Med"}],"container-title":["Psychosomatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033318211002374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033318211002374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T18:37:44Z","timestamp":1563907064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033318211002374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0033318211002374"],"URL":"https:\/\/doi.org\/10.1016\/j.psym.2011.06.001","relation":{},"ISSN":["0033-3182"],"issn-type":[{"value":"0033-3182","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}